Read More
💡 Johnson & Johnson: $14.6 billion acquisition strengthens the pharmaceutical giant's position in the neurological drugs market 💊
Johnson & Johnson $JNJ, one of the biggest players in the healthcare industry, has once again shown that growth through strategic acquisitions is their forte.
The company announced last week the purchase of biopharmaceutical firm Intra-Cellular...
Read more
It's not a bad business, but I'd rather buy something riskier. Plus this stock isn't growing as mentioned and I don't see why it should start growing.